Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope

Abstract

Small cell lung cancer (SCLC) is a devastating and aggressive neuroendocrine carcinoma of the lung. It accounts for ~15% of lung cancer mortality and has had no improvement in standard treatment options for nearly 30 years. However, there is now hope for change with new therapies and modalities of therapy. Immunotherapies and checkpoint inhibitors are entering clinical practice, selected targeted therapies show promise, and "smart bomb"-based drug/radioconjugates have led to good response in early clinical trials. Additionally, new research insights into the genetics and tumor heterogeneity of SCLC alongside the availability of new tools such as patient-derived or circulating tumor cell xenografts offer the potential to shine light on this beshadowed cancer.

Keywords: Antibody drug conjugates; BCL2; CTLA4; Immunotherapy; PARP inhibitor; PDL1; Peptide receptor radionuclide therapy; Small cell lung cancer.